15 August 2018 - - UK-based Bactevo Ltd. has named professor Pietro Lio of the Computer Laboratory in Cambridge University to its scientific advisory board, the company said.

Bactevo said that Lio brings a wealth of skills from the disciplines of bioinformatics and machine learning.

During his distinguished career, Lio has pioneered the development and testing of novel methodologies for modelling biomolecular processes for complex diseases and co-morbidities.

Bactevo also announces an immediate change of company name to Nanna Therapeutics.

The name change has been instigated to reflect evolution of the company's business strategy around a 21st century approach to the generation of new medicines.

By leveraging tools such as advanced machine learning to unlock the full power of its proprietary TIME platform, which couples unique 'tagless' encoded small-molecule library generation with ultra-high throughput microfluidics-based screening capabilities, the company believes the process of drug discovery and development can be transformed.

Nanna Therapeutics has built a unique, game-changing Totally Integrated Medicines Engine to create novel therapeutics.

Enabled by advanced machine learning, TIME utilises its paradigm shift in the speed, efficiency and quality of drug discovery, as well as dramatically enhanced safety profiling, to improve clinical success.

In addition to working with partners to develop novel first-in-class medicines in multiple disease areas, Nanna Therapeutics is developing breakthrough medicines for the treatment of age-related diseases, focusing first on those affecting mitochondrial function, such as MELAS, as well as diseases of the central nervous system including Parkinson's disease and Amyotrophic Lateral Sclerosis.